ALK B ALK-ABELLO A/S

Invitation to the presentation of ALK’s annual report 2025 on Friday, 20 February 2026

Invitation to the presentation of ALK’s annual report 2025 on Friday, 20 February 2026

ALK (ALKB:DC / OMX: ALK B) will publish its annual report for 2025 in the morning on Friday, 20 February 2026.

Later on the same day, the company will host a presentation for investors and analysts at 1:30 p.m. CET, where ALK’s management will comment on the results and outlook and be available for questions.

ALK will be represented by Peter Halling, President & CEO, Claus Steensen Sølje, CFO and Per Plotnikof, VP, Head of IR. 

Live audio webcast

The meeting will be audio webcasted live and be available for replay on .

Conference call

If you wish to participate via telephone, please register for the conference call by using this link: and follow the instructions. You will receive an email from with dial-in details, including a passcode and a pin code. Please make sure to whitelist  and/or check your spam filter. We advise you to register on the day before the call at the latest.

Presentation

The presentation will be available on shortly before the meeting starts.

ALK-Abelló A/S

For further information please contact:

Investor Relations: Per Plotnikof, tel. , mobile

Media: Maiken Riise Andersen, tel.

About ALK

ALK is a global specialty pharmaceutical company focused on allergy. ALK's activities cover the entire value chain of developing, sourcing, producing, and marketing a diversified portfolio of products for diagnosing and treating respiratory allergies and severe allergic reactions (anaphylaxis) in both children and adults. Headquartered in Denmark, ALK employs around 2,700 people worldwide and is listed on Nasdaq Copenhagen (Nasdaq: ALK B). Visit us at .

Attachment



EN
13/02/2026

Underlying

ALK BALK-ABELLO A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ALK-ABELLO A/S

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
02/23/26 February 23, 2026 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

Ordinær generalforsamling i ALK-Abelló A/S den 16. marts 2026

Ordinær generalforsamling i ALK-Abelló A/S den 16. marts 2026 Ordinær generalforsamling i ALK-Abelló A/S (ALKB:DC / Nasdaq Copenhagen: ALK B) finder sted mandag den 16. marts 2026 kl. 16.00 hos ALK-Abelló A/S, Bøge Allé 1, 2970 Hørsholm i henhold til vedhæftede indkaldelse med bestyrelsens fuldstændige forslag, som fremsættes på generalforsamlingen. ALK-Abelló A/S For yderligere oplysninger kontakt venligst:Investor Relations: Per Plotnikof, tlf. 4574 7527, mobil 2261 2525Presse: Maiken Riise Andersen, tlf. 5054 1434 Om ALKALK er en global, specialiseret medicinalvirksomhed med fok...

February 20, 2026 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

Annual General Meeting in ALK-Abelló A/S on 16 March 2026

Annual General Meeting in ALK-Abelló A/S on 16 March 2026 The Annual General Meeting of ALK-Abelló A/S (ALKB:DC / Nasdaq Copenhagen: ALK B) will take place on Monday, 16 March 2026 at 4:00 PM (CET) at ALK-Abelló A/S, Bøge Allé 1, 2970 Hørsholm, Denmark. The agenda of the meeting including the complete proposals from the Board of Directors to the AGM is attached. ALK-Abelló A/S For further information, contact: Investor Relations: Per Plotnikof, tel. , mobile Media: Maiken Riise Andersen, tel. About ALKALK is a global specialty pharmaceutical company focused on allergy. ALK's activiti...

February 20, 2026 1 EN
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
02/20/26 February 20, 2026 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

Henriette Mersebach fratræder som forskningsdirektør i ALK

Henriette Mersebach fratræder som forskningsdirektør i ALK ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) har i dag meddelt, at Henriette Mersebach fratræder som Executive Vice President, Research and Development, og som medlem af direktionen med virkning fra 23. februar 2026. Det er aftalt, at hun bistår med overlevering efter behov. Efter gensidig aftale har den administrerende direktør, bestyrelsen og Henriette Mersebach aftalt, at nu er det rette tidspunkt at udpege en ny forskningsdirektør med en anden profil for at styrke ALK’s innovationsindsats under Allergy+-strategien. Formålet er at b...

February 20, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch